Trial

NCT05998941

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborators
Condition
Cervical Cancer
Intervention
TQB2868 injection
Why stopped
Slow progress in development, the sponsor decided to withdraw and no longer proceed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-22